Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company's lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB). It is also developing ABO-101 (AAV-NAGLU) for Sanfilippo syndrome type B (MPS IIIB), ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JNCL), ABO-202 (AAV-CLN1) for treatment of infantile Batten disease (INCL), EB-201 for epidermolysis bullosa, ABO-301 (AAV-FANCC) for Fanconi anemia disorder and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood diseases. The Company also has a plasma-based protein therapy pipeline, including alpha-1 protease inhibitor (SDF Alpha) for inherited COPD, using its proprietary Salt Diafiltration ethanol-free process.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology & Medical Research
- Sub-Industry: N/A
- Symbol: NASDAQ:ABEO
- CUSIP: N/A
- Web: www.abeonatherapeutics.com
- Market Cap: $664.74 million
- Outstanding Shares: 40,287,000
- 50 Day Moving Avg: $10.74
- 200 Day Moving Avg: $7.22
- 52 Week Range: $4.05 - $17.90
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -21.15
- P/E Growth: 0.00
- Annual Revenue: $842,999.00
- Price / Sales: 788.54
- Book Value: $2.21 per share
- Price / Book: 7.47
- EBIDTA: ($23,800,000.00)
- Net Margins: -2,746.38%
- Return on Equity: -26.66%
- Return on Assets: -23.94%
- Current Ratio: 14.08%
- Quick Ratio: 14.08%
- Average Volume: 921,380 shs.
- Beta: 2.26
- Short Ratio: 7.3
Frequently Asked Questions for Abeona Therapeutics (NASDAQ:ABEO)
What is Abeona Therapeutics' stock symbol?
Abeona Therapeutics trades on the NASDAQ under the ticker symbol "ABEO."
How were Abeona Therapeutics' earnings last quarter?
Abeona Therapeutics Inc. (NASDAQ:ABEO) announced its quarterly earnings data on Tuesday, August, 15th. The company reported ($0.21) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.14) by $0.07. The company earned $0.22 million during the quarter, compared to the consensus estimate of $0.21 million. Abeona Therapeutics had a negative net margin of 2,746.38% and a negative return on equity of 26.66%. View Abeona Therapeutics' Earnings History.
When will Abeona Therapeutics make its next earnings announcement?
Where is Abeona Therapeutics' stock going? Where will Abeona Therapeutics' stock price be in 2017?
7 equities research analysts have issued 1 year price objectives for Abeona Therapeutics' shares. Their predictions range from $15.00 to $23.00. On average, they anticipate Abeona Therapeutics' stock price to reach $19.71 in the next twelve months. View Analyst Ratings for Abeona Therapeutics.
What are analysts saying about Abeona Therapeutics stock?
Here are some recent quotes from research analysts about Abeona Therapeutics stock:
- 1. According to Zacks Investment Research, "Abeona Therapeutics, Inc. is engaged in developing and delivering gene therapy and plasma-based products for rare diseases. Abeona Therapeutics Inc., formerly known as PlasmaTech Biopharmaceuticals, Inc., is based in Dallas, United States. " (8/22/2017)
- 2. Maxim Group analysts commented, "Abeona announced that the company has received guidance from the FDA for accelerating EB-101 (gene therapy corrected skin grafts) into a P3 pivotal program in epidermolysis bullosa (EB). EB-101 has demonstrated proof of concept (POC) data in the first 6 patients of the P1/2 study (Recessive Dystrophic Epidermolysis Bullosa, or RDEB), demonstrating durable wound closure, in some cases for over 3 years (standard skin graft would fall off within a few months). Pending protocol approval, the pivotal program is expected to initiate in early 2018." (7/18/2017)
- 3. Cantor Fitzgerald analysts commented, "At the ASGCT meeting in Washington D.C., Abeona announced initial 30-day data in two patients treated with a high dose of ABO-102." (5/12/2017)
- 4. FBR & Co analysts commented, "On March 31, Abeona Therapeutics reported results for a year in which all clinical programs achieved important regulatory and clinical milestones. Most notably, 2016 culminated in the initiation of dosing in the high-dose cohort of Abeona’s Phase I/II trial with ABO-102 in children with Sanfilippo Syndrome Type A (MPS IIIA). We think this milestone is significant as it highlights ABO-102’s continued safety, its promising biopotency, as well as its designation for FDA Fast Track status for a rare pediatric disease, as well as for an orphan disease. It also supports our view that Abeona’s ability to rapidly advance therapies with high-value potential and short pathways to regulatory approval remains under-appreciated. We look next for a clinical update on the EB-101 Phase I study later this month, an update on the Phase I/II study with ABO-101 in MPS IIIB, as well as Abeona’s three other ongoing rare disease programs in the next three to six months to be positive catalysts for ABEO stock." (4/5/2017)
Who are some of Abeona Therapeutics' key competitors?
Some companies that are related to Abeona Therapeutics include Immunomedics (IMMU), Global Blood Therapeutics (GBT), Genus plc (GNS), Momenta Pharmaceuticals (MNTA), Medpace Holdings (MEDP), Esperion Therapeutics (ESPR), Genomic Health (GHDX), Cellectis S.A. (CLLS), Arena Pharmaceuticals (ARNA), Editas Medicine (EDIT), Albany Molecular Research (AMRI), BeyondSpring (BYSI), Intellia Therapeutics (NTLA), Enanta Pharmaceuticals (ENTA), Heron Therapeutics (HRTX), Spectrum Pharmaceuticals (SPPI), Crispr Theraptc (CRSP) and TG Therapeutics (TGTX).
Who are Abeona Therapeutics' key executives?
Abeona Therapeutics' management team includes the folowing people:
- Steven H. Rouhandeh, Executive Chairman of the Board
- Timothy J. Miller Ph.D., President, Chief Executive Officer, Director
- Jeffrey B. Davis, Chief Operating Officer
- David P. Nowotnik Ph.D., Senior Vice President - Research and Development
- Harrison G. Wehner III, Senior Vice President - Plasma
- Stephen B. Thompson, Chief Accounting Officer, Vice President - Finance, Treasurer, Secretary
- Michelle Berg, Vice President - Communications & Operations
- Andre'a Lucca, Vice President - Communications & Operations
- Phil Maples Ph.D., Vice President - Therapeutics Development and Quality Management
- Kaye Spratt Ph.D., Vice President - Regulatory & Quality Assurance
Who owns Abeona Therapeutics stock?
Abeona Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (2.69%), Nexthera Capital LP (0.88%), Royce & Associates LP (0.78%), State Street Corp (0.74%), Northern Trust Corp (0.64%) and Bank of New York Mellon Corp (0.25%). View Institutional Ownership Trends for Abeona Therapeutics.
Who sold Abeona Therapeutics stock? Who is selling Abeona Therapeutics stock?
Who bought Abeona Therapeutics stock? Who is buying Abeona Therapeutics stock?
Abeona Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including State Street Corp, Northern Trust Corp, Vanguard Group Inc., Essex Investment Management Co. LLC, TIAA CREF Investment Management LLC, Bank of New York Mellon Corp, Teachers Advisors LLC and California State Teachers Retirement System. View Insider Buying and Selling for Abeona Therapeutics.
How do I buy Abeona Therapeutics stock?
Shares of Abeona Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Abeona Therapeutics' stock price today?
MarketBeat Community Rating for Abeona Therapeutics (NASDAQ ABEO)MarketBeat's community ratings are surveys of what our community members think about Abeona Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Abeona Therapeutics stock can currently be purchased for approximately $16.50.
Earnings History for Abeona Therapeutics (NASDAQ:ABEO)Earnings History by Quarter for Abeona Therapeutics (NASDAQ ABEO)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/13/2017|| || || || || || || || |
|8/15/2017||Q2 2017||($0.14)||($0.21)||$0.21 million||$0.22 million||View||N/A|
|5/18/2017||Q1 2017||($0.15)||($0.13)||$0.28 million||$0.19 million||View||N/A|
|3/31/2017||12/31/2016||($0.14)||($0.19)||$0.19 million||$0.26 million||View||N/A|
|11/14/2016||Q316||($0.19)||($0.08)||$0.23 million||$0.18 million||View||N/A|
|8/16/2016||Q2||($0.14)||($0.20)||$0.27 million||$0.21 million||View||N/A|
Earnings Estimates for Abeona Therapeutics (NASDAQ:ABEO)
2017 EPS Consensus Estimate: ($0.47)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Abeona Therapeutics (NASDAQ:ABEO)
No dividend announcements for this company have been tracked by MarketBeat.com
Headline Trends for Abeona Therapeutics (NASDAQ:ABEO)
Latest Headlines for Abeona Therapeutics (NASDAQ:ABEO)
| Analysts Expect Abeona Therapeutics Inc. (ABEO) Will Post Quarterly Sales of $230,000.00|
www.americanbankingnews.com - September 19 at 3:00 AM
|ETFs with exposure to Abeona Therapeutics, Inc. : September 18, 2017|
finance.yahoo.com - September 18 at 8:32 PM
|Abeona Therapeutics (ABEO) Surges: Stock Moves 22.9% Higher - Yahoo Finance|
finance.yahoo.com - September 18 at 3:23 PM
|Abeona Therapeutics (ABEO) Surges: Stock Moves 22.9% Higher|
finance.yahoo.com - September 18 at 3:23 PM
|RBC Capital's Marc Harris breaks down his best biotech pi...|
finance.yahoo.com - September 18 at 3:23 PM
|HC Wainwright Reiterates Buy Rating for Abeona Therapeutics Inc. (ABEO)|
www.americanbankingnews.com - September 18 at 10:16 AM
|-$0.16 Earnings Per Share Expected for Abeona Therapeutics Inc. (ABEO) This Quarter|
www.americanbankingnews.com - September 18 at 12:28 AM
|Mid-Day Market Update: Mirati Therapeutics Climbs Following Positive Sitravatinib Data; First Internet Bancorp ... - Benzinga|
www.benzinga.com - September 15 at 3:15 PM
|How Should You Think About Abeona Therapeutics Inc’s (ABEO) Risks?|
finance.yahoo.com - September 15 at 3:15 PM
|Abeona Therapeutics Inc. (ABEO) Now Covered by Analysts at Royal Bank Of Canada|
www.americanbankingnews.com - September 14 at 5:26 PM
|Abeona Therapeutics Inc. (ABEO) Given Consensus Recommendation of "Buy" by Brokerages|
www.americanbankingnews.com - September 13 at 5:06 PM
|Head to Head Contrast: Abeona Therapeutics (ABEO) vs. Arbutus Biopharma Corporation (ABUS)|
www.americanbankingnews.com - September 12 at 12:28 AM
|Abeona Therapeutics Inc. (ABEO) Stock Rating Reaffirmed by HC Wainwright|
www.americanbankingnews.com - September 8 at 6:44 PM
|Biotechs On The Move - Forbes|
www.forbes.com - August 31 at 8:17 PM
|ETFs with exposure to Abeona Therapeutics, Inc. : August 31, 2017|
finance.yahoo.com - August 31 at 8:17 PM
|Opinion: Harry Boxer's four biotech stocks to watch - MarketWatch|
www.marketwatch.com - August 30 at 8:17 PM
|Zacks: Analysts Expect Abeona Therapeutics Inc. (ABEO) Will Post Earnings of -$0.16 Per Share|
www.americanbankingnews.com - August 30 at 12:18 PM
|APRI Makes 2nd Try, PRQR To Reveal Data On Sep.25, PFE Awaits FDA Decision - Nasdaq|
www.nasdaq.com - August 30 at 5:17 AM
|BRIEF-Abeona Therapeutics receives FDA breakthrough therapy designation for EB-101|
www.reuters.com - August 29 at 3:28 PM
|Abeona Therapeutics Receives FDA Breakthrough Therapy Designation for EB-101 Autologous Cell Therapy in Epidermolysis Bullosa|
finance.yahoo.com - August 29 at 3:28 PM
|Abeona Therapeutics Inc. (ABEO) Given a $17.00 Price Target at Maxim Group|
www.americanbankingnews.com - August 29 at 1:04 PM
|Abeona Therapeutics Inc. (ABEO) to Post FY2017 Earnings of ($0.74) Per Share, Cantor Fitzgerald Forecasts|
www.americanbankingnews.com - August 28 at 3:38 AM
|Abeona Therapeutics: Transitioning To Late-Stage Studies - Seeking Alpha|
seekingalpha.com - August 27 at 3:16 PM
|Pro-Trader Daily: Corporate News Blog - BioDelivery Sciences CEO Dr. Mark A. Sirgo to Retire at Year-End; Will Continue as Vice Chairman|
www.finanznachrichten.de - August 25 at 4:56 PM
|Corporate News Blog - BioDelivery Sciences CEO Dr. Mark A. Sirgo to Retire at Year-End; Will Continue as Vice Chairman|
finance.yahoo.com - August 25 at 4:56 PM
|Abeona Therapeutics, Inc. :ABEO-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017|
finance.yahoo.com - August 24 at 3:18 PM
|Abeona Therapeutics' (ABEO) Buy Rating Reaffirmed at HC Wainwright|
www.americanbankingnews.com - August 24 at 8:06 AM
|Edited Transcript of ABEO earnings conference call or presentation 22-Aug-17 2:00pm GMT|
finance.yahoo.com - August 23 at 1:33 AM
|Abeona Therapeutics Inc. (ABEO) Lowered to Sell at Zacks Investment Research|
www.americanbankingnews.com - August 22 at 10:40 PM
|Abeona Therapeutics - String Of Pearls Strategy With Numerous ... - Seeking Alpha|
seekingalpha.com - August 22 at 8:32 PM
|Abeona Therapeutics Inc. (ABEO) Receives Consensus Rating of "Buy" from Brokerages|
www.americanbankingnews.com - August 19 at 3:16 PM
|Jefferies Group Comments on Abeona Therapeutics Inc.'s Q3 2017 Earnings (ABEO)|
www.americanbankingnews.com - August 18 at 7:20 AM
|Abeona Therapeutics to Host Gene Therapy R&D Day on October 11, 2017 - Nasdaq|
www.nasdaq.com - August 18 at 1:35 AM
|Leading Biotech Companies Receiving Orphan Drug Designation in 2017|
www.bizjournals.com - August 17 at 3:31 PM
|ABEONA THERAPEUTICS INC|
www.finanznachrichten.de - August 17 at 3:31 PM
|Abeona Therapeutics to Host Gene Therapy R&D Day on October 11, 2017|
feeds.benzinga.com - August 17 at 9:55 AM
|Abeona Therapeutics Inc. (ABEO) Cut to "Hold" at Zacks Investment Research|
www.americanbankingnews.com - August 16 at 9:34 PM
|BRIEF-Abeona Therapeutics expands gene therapy clinical trials in Sanfilippo Syndrome Type A|
www.reuters.com - August 16 at 8:24 PM
|Abeona Therapeutics Announces Pivotal Expansion of ABO-102 Gene Therapy Clinical Trials in Sanfilippo Syndrome ... - GlobeNewswire (press release)|
globenewswire.com - August 16 at 3:21 PM
|Abeona Therapeutics Announces Pivotal Expansion of ABO-102 Gene Therapy Clinical Trials in Sanfilippo Syndrome Type A|
finance.yahoo.com - August 16 at 3:21 PM
|Maxim Group Analysts Give Abeona Therapeutics Inc. (ABEO) a $17.00 Price Target|
www.americanbankingnews.com - August 16 at 3:12 PM
|Abeona Therapeutics Inc. (ABEO) Releases Earnings Results, Misses Expectations By $0.07 EPS|
www.americanbankingnews.com - August 16 at 10:38 AM
|Abeona Therapeutics Reports Second Quarter 2017 Financial Results and Recent Business Highlights - GlobeNewswire (press release)|
globenewswire.com - August 15 at 3:22 PM
|Abeona Therapeutics Reports Second Quarter 2017 Financial Results and Recent Business Highlights|
finance.yahoo.com - August 15 at 3:22 PM
|Abeona Therapeutics reports 2Q loss|
finance.yahoo.com - August 15 at 3:22 PM
| Brokerages Anticipate Abeona Therapeutics Inc. (ABEO) Will Post Quarterly Sales of $230,000.00|
www.americanbankingnews.com - August 14 at 10:14 AM
| Analysts Anticipate Abeona Therapeutics Inc. (NASDAQ:ABEO) Will Post Earnings of -$0.12 Per Share|
www.americanbankingnews.com - August 12 at 2:12 AM
|Top Companies Receiving Orphan Drug Designation in 2017|
www.prnewswire.com - July 28 at 3:28 PM
|Abeona Therapeutics Inc. (NASDAQ:ABEO) Expected to Announce Quarterly Sales of $230,000.00|
www.americanbankingnews.com - July 26 at 10:37 AM
|Abeona Therapeutics (ABEO) Appoints Juan Ruiz as CMO - StreetInsider.com|
www.streetinsider.com - July 26 at 1:22 AM
Abeona Therapeutics (ABEO) Chart for Wednesday, September, 20, 2017